Setting Up a Haplobank: Issues and Solutions

Current Stem Cell Reports

Volumn 1, Issue 2, 2015, Pages 110-117

  Barry, Jacqueline ^a   Hyllner, Johan ^a,b   Stacey, Glyn ^c   Taylor, Craig J ^d   Turner, Marc ^e,f  

^a CELL AND GENE THERAPY CATAPULT   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Good manufacturing practice; HLA matching; Induced pluripotent stem cells

Indexed keywords

DONOR SELECTION; GENETIC POLYMORPHISM; GOOD MANUFACTURING PRACTICE; GRAFT REJECTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LAW; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION;

EID: 84964559412     PISSN: None     EISSN: 21987866     Source Type: Journal    
DOI: 10.1007/s40778-015-0011-7     Document Type: Review

References (28)

1. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005;366(9502):2019–25.
2. Taylor CJ, Bolton EM, Bradley JA. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci. 2011;366(1575):2312–22. doi:10.1098/rstb.2011.0030.
3. Gourraud PA, Gilson L, Girard M, Peschanski M. The role of human leukocyte antigen matching in the development of multiethnic “haplobank” of induced pluripotent stem cell lines. Stem Cells. 2012;30(2):180–6. doi:10.1002/stem.772. This paper discussed the potential utility of an HLA haplobank in providing HLA matched cell therapies.
4. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11(2):147–52. doi:10.1016/j.stem.2012.07.014.
5. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8(5):409–12. doi:10.1038/nmeth.1591.
6. Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, et al. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 2013;13(4):382–4. doi:10.1016/j.stem.2013.08.003.
7. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008;26(7):739–40. doi:10.1038/nbt0708-739.
8. Nakajima F, Tokunaga K, Nakatsuji N. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells. 2007;25(4):983–5.
9. Lin G, Xie Y, Ouyang Q, Qian X, Xie P, Zhou X, et al. HLA-matching potential of an established human embryonic stem cell bank in China. Cell Stem Cell. 2009;5(5):461–5. doi:10.1016/j.stem.2009.10.009.
10. UK Advisory Committee on the Safety of Blood, Tissues and Organs. Donation of starting material for cell-based advanced therapies. June 2014. www.gov.uk/government/uploads/system/uploads/attachment_data/file/326823/Cellular_Therapy.pdf.
11. EU Tissues and Cells Directive 2004/23/EC on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. With the following associated Commissioning Directives: Commission Directive 2006/17/EC implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. Commission Directive 2012/39/EU amending Directive 2006/17/EC as regards certain technical requirements for the testing of human tissues and cells. Commission Directive 2006/86/EC implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells.
12. EU Blood Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. With the following associated Commissioning Directives: Commission Directive 2004/33/EC implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Commission Directive 2005/61/EC implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. Commission Directive 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council as regards Community standards and specifications relating to a quality system for blood establishments.
13. Food and Drug Administration, Codes of Federal Regulation Title 21
14. Stacey G. The challenge of standardisation in stem cell research and development. Chapter2 In: Ilic D editors. Stem cell banking. Springer; 2014, chapter 2, pp. 11–18. This papers draws out the importance and challenges of establishing internationally recognised standards in stem cell and cell therapy manufacture.
15. Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell. 2013;13:149–59.
16. Peterson, SE, Westra, JW, Rehen, SK, et al. Normal human pluripotent stem cell lines exhibit pervasive mosaic aneuploidy. PLoS One. 2011;6(8):e23018.
17. Tompkins JD, Hall C, Chen VC, et al. Epigenetic stability, adaptability, and reversibility in human embryonic stem cells. Proc Natl Acad Sci U S A. 2012;109(31):12544–9.
18. Andrews PW, et al. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications. Regen Med. 2015;10(02s):1–44. This paper draws on expert opinion from stem cell banks, stem cell biologists, scientific societies and regulators in 24 countries active in stem cell research and thus represents a powerful consensus from the field on what is required to establish for seed stocks of hPSC lines for clinical use.
19. Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212–5.
20. Awe JP, Lee PC, Ramathal C, et al. Generation and characterisation of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther. 2013;4:87.
21. Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use
22. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended
23. Japanese Ministry of Health, Labour and Welfare Guidelines on clinical research using human Stem Cells 2006
24. Bravery CA. Do human leukocyte antigen typed cellular therapeutics based on induced pluripotent stem cells make commercial sense. Stem Cells Dev. 2014. doi:10.1089/scd.2014.0136.
25. Andrews PW, Cavanagro J, Deans R, Feigel E, Horowitz E, Keating A, Rao M, Turner M. Wilmut I, Yamanaka S. Harmonising standards for producing clinical-grade therapies from pluripotent stem cells. Nat Biotechnol. 2014;32(8):724–6.
26. Silva M, Daheron L, Hurley H, et al. Generating iPSCs: translating cell reprogramming science into scalable and robust manufacturing strategies. Cell Stem Cell. 2015;16:13–7.
27. Wilmut I, Leslie S, Martin NG, Peschanski M, Rao M, Trounson A, et al. Development of a global network of induced pluripotent stem cell haplobanks. Regen Med. 2015; in press. This paper makes the argument for the establishment of global collaboration in the establishment of standards for GMP iPSC manufacture.
28. Sheridan B, Stacey G, Wilson A, Ginty P, Bravery C, Marshall D. Standards can help bring products to market. Bioproc Int. 2012;10(4):18–20.